Pilot experience evaluates feasibility and safety of home-based cancer immunotherapy, suggesting improved patient-centered care.
Home-based administration of cancer immunotherapy (IO) is an emerging care model aimed at improving patient-centered care and accessibility. However, real-world evidence regarding its feasibility, safety, and patient experience remains limited.
No takes yet. Share an insight, caveat, or question.
Rubio et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: